MedPath

Effect and safety of conversion from Candesartan to Azilsartan in renal transplant recipeints

Not Applicable
Conditions
hypertensive patient
Registration Number
JPRN-UMIN000008989
Lead Sponsor
Soryukai Inoue Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1)Past medical history of hypersensitivity to azilsartan 2)Pregnant,lactating,and possibly pregnant women and those planning to become pregnant 3)Judged as ineligible by clinical investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
rine protein before,3 months,6 months,and 12 months after the conversion
Secondary Outcome Measures
NameTimeMethod
Blood pressure,albumin,creatinen,potasium,hemoglubin,plasma renin activity,plasma aldosterone concentarion and MCP-1 before,3 months,6 months,and 12 months after the conversion
© Copyright 2025. All Rights Reserved by MedPath